Oseltamivir in the management of influenza.

abstract：INTRODUCTION:The late effects of cancer treatment have recently gained a worldwide ubiquitous interest among reproductive endocrinologists, oncologists, and all health care providers. Despite many publications on this subject, there are many equivocal issues necessitating summary. The case for and against using GnRH-ag...

journal_title：Expert opinion on pharmacotherapy

authors： Blumenfeld Z,Evron A

更新日期：2015-05-01 00:00:00

abstract：BACKGROUND:Patients with rheumatoid arthritis (RA) have an increased risk of atherosclerotic cardiovascular disease which cannot be explained by traditional cardiovascular risk factors alone. Atherosclerosis is considered an inflammatory condition and inflammation experienced in RA may contribute to accelerated atheros...

journal_title：Expert opinion on pharmacotherapy

authors： Avouac J,Allanore Y

更新日期：2008-05-01 00:00:00

abstract：INTRODUCTION:PI3K inhibition with idelalisib (at that time CAL-101) was at the forefront of the development of molecularly targeted therapies in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) and follicular lymphoma. However, after initial approval, subsequent trials identified specific immune-medi...

journal_title：Expert opinion on pharmacotherapy

authors： Kienle DL,Stilgenbauer S

更新日期：2020-06-01 00:00:00

abstract：BACKGROUND:Acute pulmonary embolism (PE) is a life-threatening condition that has been treated with anticoagulation for almost 50 years. OBJECTIVES:To review the current treatment options for PE and discuss recently published new features. METHODS:We reviewed literature involving the treatment strategies for venous t...

journal_title：Expert opinion on pharmacotherapy

authors： Blondon M,Bounameaux H,Righini M

更新日期：2009-05-01 00:00:00

abstract：INTRODUCTION:Only 40-60% of obsessive-compulsive patients respond to first line treatments, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy. Several second-line treatments have been investigated in the last two decades, and most of them seem to work, at least in a subset of pati...

journal_title：Expert opinion on pharmacotherapy

authors： Grassi G,Pallanti S

更新日期：2018-10-01 00:00:00

abstract：:Pregnancies complicated by diabetes mellitus (DM) include pregestational DM and gestational DM, defined as carbohydrate intolerance of variable severity first detected during pregnancy. DM leads to poor pregnancy outcome. The aim of treatment is to control maternal hyperglycaemia and to imitate postprandial insulin re...

journal_title：Expert opinion on pharmacotherapy

authors： González C,Santoro S,Salzberg S,Di Girolamo G,Alvariñas J

更新日期：2005-05-01 00:00:00

abstract：:Motor fluctuations are common and distressing for patients with advanced Parkinson's disease. Subcutaneous apomorphine injections can be an extremely valuable adjunctive therapy. In this review, the authors discuss the history, pharmacology, efficacy, safety and proper administration of apomorphine for treating 'off' ...

journal_title：Expert opinion on pharmacotherapy

authors： Haq IU,Lewitt PA,Fernandez HH

更新日期：2007-11-01 00:00:00

abstract：:Motor fluctuations are a common problem in the long-term management of Parkinson's disease (PD), resulting in disability and impaired quality of life. The relatively short serum half-life (approximately 90 min) of oral levodopa/carbidopa and its erratic absorption due to delayed and inconsistent gastric emptying (a no...

journal_title：Expert opinion on pharmacotherapy

authors： Samanta J,Hauser RA

更新日期：2007-04-01 00:00:00

abstract：:Symptomatic and asymptomatic peripheral arterial occlusive disease (PAD) is indicative of widespread atherosclerosis. The major threat is from cardiovascular ischaemic events; thus, an important therapeutic goal is to modify atherosclerotic risk factors. Data from several large drug trials indicate that patients with ...

journal_title：Expert opinion on pharmacotherapy

authors： Baumgartner I

更新日期：2005-10-01 00:00:00

abstract：BACKGROUND:5-Aminolaevulinic acid (ALA) is the naturally occurring metabolic precursor of an endogenously formed photosensitiser, protoporphyrin IX. It is used topically to treat benign and malignant skin disorders by a process called photodynamic therapy (PDT). Recently, data are emerging on its systemic use in the tr...

journal_title：Expert opinion on pharmacotherapy

authors： Dunn J,Lovat L

更新日期：2008-04-01 00:00:00

abstract：:This paper describes the functional roles of the closely related pharmacogenetic and pharmacogenomic sciences in medicine. Firstly, they provide means for a better understanding of the function of drugs, and particularly of the differences of drug action between individuals and also between racially categorised popula...

journal_title：Expert opinion on pharmacotherapy

authors： Kalow W

更新日期：2005-07-01 00:00:00

abstract：:Vascular injury is a ubiquitous phenomenon which can be both occult (such as with hyperlipidemia) and overt (such as with angioplasty). While the exact pathophysiology differs between acute and chronic atherosclerosis, both lesions can be mechanistically explained by the vasculature's exaggerated response to injury. P...

journal_title：Expert opinion on pharmacotherapy

authors： Selzman CH

更新日期：2001-05-01 00:00:00

abstract：:Neonates in the neonatal intensive care unit experience hundreds of painful procedures at a time of rapid neurological development. Although the immediate responses to pain may be protective, the potential long-term effects of early and under-treated pain are concerning. As pain assessment is the first step in the pro...

journal_title：Expert opinion on pharmacotherapy

authors： Gibbins S,Stevens B,Asztalos E

更新日期：2003-04-01 00:00:00

abstract：INTRODUCTION:The introduction of novel agents has significantly improved multiple myeloma (MM) patient outcome during the last two decades. MM received the most drug approvals for any one malignancy during this time period, both in the United States as well as in Europe. Areas covered: Proteasome inhibitors, immunomodu...

journal_title：Expert opinion on pharmacotherapy

authors： Podar K,Pecherstorfer M

更新日期：2017-08-01 00:00:00

abstract：:Peglyated liposomal doxorubicin was developed to maintain or enhance the demonstrated antineoplastic effects of doxorubicin, while improving the toxicity profile associated with this important cytotoxic agent. Accumulating clinical data have confirmed the activity of pegylated liposomal doxorubicin in cancers of the b...

journal_title：Expert opinion on pharmacotherapy

authors： Markman M

更新日期：2006-08-01 00:00:00

abstract：INTRODUCTION:Human respiratory syncytial virus (hRSV) is the primary viral cause of respiratory diseases, leading to bronchiolitis and pneumonia in vulnerable populations. The only current treatment against this virus is palliative, and no efficient and specific vaccine against this pathogen is available. AREAS COVERE...

journal_title：Expert opinion on pharmacotherapy

authors： Kalergis AM,Soto JA,Gálvez NMS,Andrade CA,Fernandez A,Bohmwald K,Bueno SM

更新日期：2020-12-01 00:00:00

abstract：:The objective of this article is to evaluate the roles of the lipid-lowering class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in reducing cardiovascular events and to review their mechanism of action based on in vitro and in vivo studies. The clinical outcome of 15 major clinical...

journal_title：Expert opinion on pharmacotherapy

authors： Moghadasian MH,Mancini GB,Frohlich JJ

更新日期：2000-05-01 00:00:00

abstract：INTRODUCTION:Adjunctive pharmacotherapy is of key importance in determining the outcomes of percutaneous coronary intervention (PCI). In parallel, there has been an increasing body of evidence indicating that the aggressive management of coronary risk factors and changes in lifestyle behavior yield additional positive ...

journal_title：Expert opinion on pharmacotherapy

authors： Capodanno D,Tamburino C,Dangas G

更新日期：2011-05-01 00:00:00

abstract：:Osteosarcoma is the most frequent primary cancer of bone. When treated by surgery alone, it is almost invariably followed by metastatic dissemination and death. This dismal prognosis can be improved dramatically by including chemotherapy in an interdisciplinary regimen. Today, two-thirds of patients with localised ext...

journal_title：Expert opinion on pharmacotherapy

authors： Bielack SS,Machatschek JN,Flege S,Jürgens H

更新日期：2004-06-01 00:00:00

abstract：:HIV-1/highly active antiretroviral therapy-associated lipodystrophy syndrome (HALS) is presently the most common long-term adverse effect limiting the doubtless efficacy of antiretroviral therapy. It has a great impact on the quality of life of patients, it is stigmatising and its psychologically devastating consequen...

journal_title：Expert opinion on pharmacotherapy

authors： del Mar Gutierrez M,Mateo G,Domingo P

更新日期：2007-08-01 00:00:00

abstract：INTRODUCTION:Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from stu...

journal_title：Expert opinion on pharmacotherapy

authors： Carrion AF,Gutierrez J,Martin P

更新日期：2014-04-01 00:00:00

abstract：:Anorexia is a frequent complication of uraemic syndrome, which contributes to malnutrition in dialysis patients. Uraemic anorexia has been associated with many factors. This paper reviews the current knowledge about mechanisms responsible for uraemic anorexia, the treatments and new drugs used to control the loss of a...

journal_title：Expert opinion on pharmacotherapy

authors： Aguilera A,Selgas R,Diéz JJ,Bajo MA,Codoceo R,Alvarez V

更新日期：2001-11-01 00:00:00

abstract：INTRODUCTION:Glaucoma is the second leading cause of blindness globally, representing a significant public health concern. More than 60 million people are affected by glaucoma worldwide; as this population ages, the number is expected to increase. Glaucoma is a collection of heterogeneous diseases sharing common clinic...

journal_title：Expert opinion on pharmacotherapy

authors： Konstas AG,Quaranta L,Realini T

更新日期：2012-04-01 00:00:00

abstract：INTRODUCTION:Hyperphosphatemia in chronic kidney disease (CKD) is considered as an independent risk factor for surrogate clinical end points like vascular calcification (VC) and bone disease, or hard clinical outcomes like cardiovascular events. Various treatment options are available for phosphate removal or reduction...

journal_title：Expert opinion on pharmacotherapy

authors： Spasovski G

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:As type 2 diabetes mellitus (T2DM) advances, patients receiving basal insulin will eventually require another agent on top of their current regimen in order to achieve glycemic control. One such agent that can be administered in combination with basal insulin is the glucagon-like peptide-1 receptor agonist...

journal_title：Expert opinion on pharmacotherapy

authors： Forst T

更新日期：2016-08-01 00:00:00

abstract：:In recent years, hepatitis C virus-related arthritis (HCVrA) has been recognised as an autonomous rheumatic disorder. Two subsets of the disease have been identified: a polyarthritis involving small joints that resembles rheumatoid arthritis, but is usually milder, and a mono-oligoarthritis that shows an intermittent ...

journal_title：Expert opinion on pharmacotherapy

authors： Palazzi C,Olivieri I,Cacciatore P,Pennese E,D'Amico E

更新日期：2005-01-01 00:00:00

abstract：:Memantine is the first and only medication that has been approved by European, US and Canadian regulatory agencies for the treatment of moderate-to-severe Alzheimer's disease (AD). It is an NMDA receptor antagonist that works to prevent excitotoxicity and cell death, which are mediated by the excessive influx of calci...

journal_title：Expert opinion on pharmacotherapy

authors： Cosman KM,Boyle LL,Porsteinsson AP

更新日期：2007-02-01 00:00:00

abstract：:Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic therapies. Areas covered: The authors provide a...

journal_title：Expert opinion on pharmacotherapy

authors： Al-Khersan H,Hussain RM,Ciulla TA,Dugel PU

更新日期：2019-10-01 00:00:00

abstract：:Phosphorus binders are used in patients with kidney failure because of the incomplete removal of phosphorus with dialysis and the inability to exclude phosphorus from the diet. Aluminium was the initial phosphorus binder used, but was replaced by calcium-containing binders because of the development of aluminium toxic...

journal_title：Expert opinion on pharmacotherapy

authors： Bleyer AJ

更新日期：2003-06-01 00:00:00

abstract：:Chronic kidney diseases frequently advance to end-stage renal failure, and the number of patients affected is steadily increasing worldwide. At the molecular level, progression of renal insufficiency correlates closely with ongoing pathological matrix protein expansion (i.e., renal fibrosis), in a manner independent o...

journal_title：Expert opinion on pharmacotherapy

authors： Gaedeke J,Neumayer HH,Peters H

更新日期：2006-03-01 00:00:00